September 19, 2017 / 3:00 PM / a year ago

BRIEF-Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states

Sept 19 (Reuters) - Teva Pharmaceutical Industries Ltd

* Teva and Nuvelution Pharma partner to accelerate development of austedo® (deutetrabenazine) tablets for use in tourette syndrome in the united states

* Teva Pharmaceutical Industries Ltd - upon fda approval of austedo® in ts, teva will pay nuvelution a pre-agreed return on its invested capital

* Teva - ‍under terms of agreement, Nuvelution will fund and manage clinical development, driving all operational aspects of Phase III Program​

* Teva Pharmaceutical Industries Ltd - ‍ under terms, Teva will lead regulatory process and be responsible for commercialization of austedo tablets​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below